Alivus Life Sciences Gears Up for Q3 Reveal on 22nd January; Check Key Expectations Here

Alivus Life Sciences Q3 FY26 results are scheduled to be announced on 22nd January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Alivus Life Sciences Q3 Results 2026 Preview

• Alivus Life Sciences’ revenue is expected to be in the range of ₹641.84 crore, up 26.63% YoY. 
• Profit After Tax, or PAT, is projected to rise by 43.69% YoY. 
• Alivus Life Sciences’ EBITDA is expected to rise to ₹175.15 crore. 
• Net profit is ₹136.96 crore, up 43.69% YoY 

Alivus Life Sciences Share Performance 

• Over the past six months, Alivus Life Sciences’ share price has fallen by 18.28% to ₹862.90.
• Moreover, over the past year, the stock has decreased by 24.96%.
• Despite this weak short-term performance, Alivus Life Sciences’ stock has delivered a financially sound 24.92% return over the past 5 years.
• As of 21st January 2026, the stock traded at ₹862.90 per share.

Key Factors to Watch for Alivus Life Sciences

• API Portfolio Expansion & Complex Molecules: Growth in high-value APIs and high-potency APIs (HPAPIs) boosts margins and enhances competitive differentiation.
• Capacity & CDMO Scale-Up: Progress in capacity expansions (Solapur, Ankleshwar, Dahej) and ramp-up of CDMO projects supports long-term revenue and utilisation.
• Geographic & Market Diversification: A broad presence in regulated markets (North America, Europe, Japan, LATAM) and a diversified customer base reduces reliance on any single region or client.
• Operational Efficiency & Financial Strength: Strong margins, healthy cash position, net-debt-free balance sheet, and disciplined cost control help sustain profitability amid pricing and raw-material pressures.

Final Thoughts

Alivus Life Sciences will announce its Q3 FY26 results on 22nd January 2026. Analysts expect 13.80% YoY revenue growth, a 303.22% rise in PAT, and a 223.80% rise in EBITDA. Alivus Life Sciences focuses on developing, manufacturing, and supplying high-quality active pharmaceutical ingredients (APIs) and CDMO services for global pharmaceutical partners.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Top 10 Penny Stocks in India | Penny Stocks to Buy in 2026

Best Stocks to Buy Today: Explore Best Stocks With Expected Trends

Milky Mist Dairy Foods IPO Details: Everything You Should Know about 

Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?

Taurian MPS IPO GMP & Review: Should You Apply or Avoid?

Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?

Dev Accelerator IPO GMP & Review: Apply or Avoid?

Vigor Plast India IPO Listing Preview: What to Expect Now?

Krupalu Metals IPO GMP: Day 3 IPO Live Updates